Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $50.31 billion. The enterprise value is $80.88 billion.
| Market Cap | 50.31B |
| Enterprise Value | 80.88B |
Important Dates
The last earnings date was Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | Sep 30, 2025 |
Share Statistics
Takeda Pharmaceutical has 1.58 billion shares outstanding. The number of shares has decreased by -0.16% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.58B |
| Shares Change (YoY) | -0.16% |
| Shares Change (QoQ) | -1.58% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 48.25% |
| Float | 1.58B |
Valuation Ratios
The trailing PE ratio is 41.71 and the forward PE ratio is 27.19.
| PE Ratio | 41.71 |
| Forward PE | 27.19 |
| PS Ratio | 1.78 |
| Forward PS | 0.02 |
| PB Ratio | 1.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 9.25 |
| P/OCF Ratio | 7.68 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.55, with an EV/FCF ratio of 14.88.
| EV / Earnings | 67.07 |
| EV / Sales | 2.85 |
| EV / EBITDA | 9.55 |
| EV / EBIT | 20.57 |
| EV / FCF | 14.88 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.70.
| Current Ratio | 1.27 |
| Quick Ratio | 0.61 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 4.05 |
| Debt / FCF | 6.31 |
| Interest Coverage | 4.77 |
Financial Efficiency
Return on equity (ROE) is 2.61% and return on invested capital (ROIC) is 3.69%.
| Return on Equity (ROE) | 2.61% |
| Return on Assets (ROA) | 2.63% |
| Return on Invested Capital (ROIC) | 3.69% |
| Return on Capital Employed (ROCE) | 4.80% |
| Weighted Average Cost of Capital (WACC) | 3.57% |
| Revenue Per Employee | $597,133 |
| Profits Per Employee | $25,414 |
| Employee Count | 47,455 |
| Asset Turnover | 0.30 |
| Inventory Turnover | 1.20 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $428.68 million in taxes.
| Income Tax | 428.68M |
| Effective Tax Rate | 26.20% |
Stock Price Statistics
The stock price has increased by +9.37% in the last 52 weeks. The beta is 0.10, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.10 |
| 52-Week Price Change | +9.37% |
| 50-Day Moving Average | 17.34 |
| 200-Day Moving Average | 15.95 |
| Relative Strength Index (RSI) | 29.14 |
| Average Volume (20 Days) | 3,086,047 |
Short Selling Information
The latest short interest is 5.00 million, so 0.32% of the outstanding shares have been sold short.
| Short Interest | 5.00M |
| Short Previous Month | 6.83M |
| Short % of Shares Out | 0.32% |
| Short % of Float | 0.32% |
| Short Ratio (days to cover) | 1.68 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $28.34 billion and earned $1.21 billion in profits. Earnings per share was $0.75.
| Revenue | 28.34B |
| Gross Profit | 18.45B |
| Operating Income | 3.93B |
| Pretax Income | 1.64B |
| Net Income | 1.21B |
| EBITDA | 8.47B |
| EBIT | 3.93B |
| Earnings Per Share (EPS) | $0.75 |
Balance Sheet
The company has $3.74 billion in cash and $34.30 billion in debt, with a net cash position of -$30.55 billion or -$19.34 per share.
| Cash & Cash Equivalents | 3.74B |
| Total Debt | 34.30B |
| Net Cash | -30.55B |
| Net Cash Per Share | -$19.34 |
| Equity (Book Value) | 48.90B |
| Book Value Per Share | 30.95 |
| Working Capital | 4.16B |
Cash Flow
In the last 12 months, operating cash flow was $6.55 billion and capital expenditures -$1.11 billion, giving a free cash flow of $5.44 billion.
| Operating Cash Flow | 6.55B |
| Capital Expenditures | -1.11B |
| Depreciation & Amortization | 4.53B |
| Net Borrowing | 6.76M |
| Free Cash Flow | 5.44B |
| FCF Per Share | $3.44 |
Margins
Gross margin is 65.12%, with operating and profit margins of 13.88% and 4.26%.
| Gross Margin | 65.12% |
| Operating Margin | 13.88% |
| Pretax Margin | 5.77% |
| Profit Margin | 4.26% |
| EBITDA Margin | 29.88% |
| EBIT Margin | 13.88% |
| FCF Margin | 19.18% |
Dividends & Yields
This stock pays an annual dividend of $0.25, which amounts to a dividend yield of 1.58%.
| Dividend Per Share | $0.25 |
| Dividend Yield | 1.58% |
| Dividend Growth (YoY) | 4.37% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 33.45% |
| Buyback Yield | 0.16% |
| Shareholder Yield | 1.71% |
| Earnings Yield | 2.40% |
| FCF Yield | 10.81% |
Analyst Forecast
The average price target for Takeda Pharmaceutical is $20.47, which is 28.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.47 |
| Price Target Difference | 28.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Takeda Pharmaceutical has an Altman Z-Score of 1.14 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.14 |
| Piotroski F-Score | 5 |